Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich s TargeTron Gene Knockout System, Celliance s Hybri-CYTE, and Peakdale Molecular s Peakexplorer GPCR Library

Premium

Sigma-Aldrich has announced the commercialization of the TargeTron Gene Knockout System. TargeTron provides a robust and simple method for site-specific disruption of DNA sequences within a host cell genome, Sigma-Aldrich said. The technology exploits the retrohoming ability of group II introns in order to “target” the exact position of gene disruption, the company said. The technology was developed by Alan Lambowitz from the University of Texas at Austin, and licensed from Ingex, Sigma-Aldrich said.


Celliance, a wholly owned subsidiary of Serologicals, has announced the introduction of Hybri-CYTE, a serum-free cell culture supplement designed and optimized for use in hybridoma cell culture. The supplement has been proven to work with mouse-, rat-, and rabbit-derived cell lines, Celliance said.


Peakdale Molecular has launched its fourth Peakexplorer GPCR library, featuring more than 1,100 compounds specifically designed, synthesized, and characterized for screening against GPCR targets. This latest library has been created through the assessment of seven chemotypes intended to target GPCRs, Peakdale said.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.